First Choice Healthcare Solutions (FCHS) 10-Q/A 17 Aug 15 2015 Q2 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 14, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	First Choice Healthcare Solutions, Inc.
Entity Central Index Key	1,416,876
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	FCHS
Entity Common Stock, Shares Outstanding		20,174,821

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash	$ 1,054,565	$ 279,087
Cash-restricted	372,822	318,259
Accounts receivable, net	4,489,477	1,804,636
Employee loans	577,286	0
Prepaid and other current assets	228,443	153,296
Capitalized financing costs, current portion	70,182	68,370
Total current assets	6,792,775	2,623,648
Property, plant and equipment, net of accumulated depreciation of $4,014,681 and $2,472,111	8,103,672	8,294,298
Other assets
Deferred costs, net of amortization of $53,774	3,172,653	0
Capitalized financing costs, long term portion	0	37,775
Patient list, net of accumulated amortization of $65,000 and $55,000	235,000	245,000
Patents, net of amortization of $28,650 and $19,100	257,850	267,400
Investments	23,026	0
Deposits	2,571	2,571
Total other assets	3,691,100	552,746
Total assets	18,587,547	11,470,692
Current liabilities
Accounts payable and accrued expenses	2,502,168	1,457,275
Stock based payable	147,500	537,750
Advances	353,000	224,000
Line of credit, short term	2,474,982	1,237,000
Convertible note payable, short term portion	1,415,920	2,148,835
Notes payable, current portion	702,950	732,791
Unearned revenue	60,876	38,763
Deferred rent, short term portion	118,810	0
Total current liabilities	7,776,206	6,376,414
Long term debt:
Deposits held	67,432	72,901
Notes payable, long term portion	8,227,555	8,184,560
Deferred rent, long term portion	1,489,636	0
Total long term debt	9,784,623	8,257,461
Total liabilities	17,560,829	14,633,875
Stockholders' equity (deficit)
Preferred stock, $0.01 par value; 1,000,000 shares authorized, Nil issued and outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 19,468,255 and 17,951,055 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	19,468	17,951
Additional paid in capital	17,465,052	12,671,942
Accumulated deficit	(16,319,116)	(15,853,076)
Total stockholders' equity (deficit) attributable to First Choice Healthcare Solutions, Inc.	1,165,404	(3,163,183)
Non-controlling interest (Note 10)	(138,686)	0
Total equity (deficit)	1,026,718	(3,163,183)
Total liabilities and equity	$ 18,733,531	$ 11,470,692

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Dec. 31, 2014
Accumulated depreciation of property plant and equipment (in dollars)	$ 4,014,681	$ 4,014,681	$ 2,472,111
Amortization of Deferred Charges, Total	53,774	53,774	0
Accumulated amortization (in dollars)	$ 65,000	$ 65,000	$ 55,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Preferred stock, issued	0	0	0
Preferred stock, outstanding	0	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	19,468,255	19,468,255	17,951,055
Common stock, shares outstanding	19,468,255	19,468,255	17,951,055
Patents [Member]
Accumulated amortization (in dollars)	$ 28,650	$ 28,650	$ 19,100

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Patient service revenue	$ 3,810,299	$ 1,885,569	$ 6,095,587	$ 3,896,543
Provision for bad debts	(6,260)	(37,128)	(51,484)	(75,272)
Net patient service revenue less provision for bad debts	3,804,039	1,848,441	6,044,103	3,821,271
Rental revenue	520,276	258,723	785,379	520,646
Total revenue	4,324,314	2,107,164	6,829,482	4,341,917
Operating expenses:
Salaries and benefits	2,125,481	1,090,806	3,071,601	2,156,327
Other operating expenses	563,422	427,056	1,014,907	856,347
General and administrative	1,649,870	669,208	2,203,154	1,075,120
Depreciation and amortization	144,417	126,772	284,926	261,491
Total operating expenses	4,483,190	2,313,842	6,574,588	4,349,285
Net income (loss) from operations	(158,875)	(206,678)	254,894	(7,368)
Other income (expense):
Miscellaneous income	40,369	750	41,119	1,500
Amortization financing costs	(19,229)	(25,466)	(39,915)	(41,372)
Interest expense, net	(358,994)	(217,177)	(722,138)	(436,430)
Total other expense	(337,854)	(241,893)	(720,934)	(476,302)
Net loss before provision for income taxes	(496,729)	(448,571)	(466,040)	(483,670)
Income taxes (benefit)	0	0	0	0
Net loss	(496,729)	(448,571)	(466,040)	(483,670)
Non-controlling interest (Note 10)	0	0	0	0
Net Loss Attributable to First Choice Healthcare Solutions, Inc.	$ (496,729)	$ (448,571)	$ (466,040)	$ (483,670)
Net loss per common share, basic and diluted	$ (0.03)	$ (0.03)	$ (0.03)	$ (0.03)
Weighted average number of common shares outstanding, basic and diluted (in shares)	18,999,475	16,988,149	18,533,559	16,873,038

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2015 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2014	$ (3,163,183)	$ 0	$ 17,951	$ 12,671,942	$ (15,853,076)	$ 0
Balance (in shares) at Dec. 31, 2014		0	17,951,055
Common stock issued for services rendered	530,000	$ 0	$ 506	529,494	0	0
Common stock issued for services rendered (in shares)		0	506,000
Common stock issued in settlement of note payable and accrued interest	811,200	$ 0	$ 811	811,389	0	0
Common stock issued in settlement of note payable and accrued interest (in shares)		0	811,200
Common stock issued in connection with loan extension	227,000	$ 0	$ 200	226,800	0	0
Common stock issued in connection with loan extension (in shares)		0	200,000
Non-controlling interest of variable interest entry	(138,686)	$ 0	$ 0	0	0	(138,686)
Fair value of options issued to acquire management control of variable interest entity	3,226,427	0	0	3,226,427	0	0
Net loss	(466,040)	0	0	0	(466,040)	0
Balance at Jun. 30, 2015	$ 1,026,718	$ 0	$ 19,468	$ 17,465,052	$ (16,319,116)	$ (138,686)
Balance (in shares) at Jun. 30, 2015		0	19,468,255

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (loss)	$ (466,040)	$ (483,670)
Adjustments to reconcile net loss to cash provided by operating activities:
Depreciation and amortization	338,700	261,491
Amortization of financing costs	39,915	41,372
Bad debt expense	51,484	75,272
Common stock issued in connection with loan extension	227,000	0
Stock based compensation	139,750	96,000
Changes in operating assets and liabilities:
Accounts receivable	(556,635)	(858,362)
Prepaid expenses and other	237,431	(85,044)
Restricted funds	(54,563)	(25,207)
Employee loans	(103,654)	0
Accounts payable and accrued expenses	160,359	453,192
Deposits	(5,469)	0
Deferred rent	39,603	0
Unearned income	22,113	(24,080)
Net cash provided by (used in) operating activities	69,994	(549,037)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash from variable interest entity	679,673	0
Purchase of equipment	(40,065)	(87,982)
Net cash used in investing activities	639,608	(87,982)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from advances	129,000	0
Proceeds from lines of credit	355,656	350,000
Net payments on notes payable	(40,065)	(381,327)
Net cash provided by (used in) financing activities	65,876	(31,327)
Net increase (decrease) in cash and cash equivalents	775,478	(668,346)
Cash and cash equivalents, beginning of period	279,087	739,158
Cash and cash equivalents, end of period	1,054,565	70,812
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for interest	594,211	436,528
Cash paid during the period for taxes	0	0
Supplemental disclosure on non-cash investing and financing activities:
Common stock issued in settlement of line of credit	0	150,000
Common stock issued in settlement of convertible note and interest	811,200	208,700
Fair value of options issued to acquire management control of variable interest entity	3,226,427	0
Line of Credit [Member]
Supplemental disclosure on non-cash investing and financing activities:
Common stock issued in settlement of accrued expenses	$ 15,000	$ 166,340

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES; BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows: General The (a) condensed consolidated balance sheet as of December 31, 2014, which has been derived from the audited financial statements of First Choice Healthcare Solutions, Inc. (“FCHS” and including, where appropriate, its consolidated subsidiaries and entities in which we have a controlling financial interest, the “Company”), and (b) the unaudited condensed consolidated interim financial statements as of June 30, 2015 of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. To determine if we hold a controlling financial interest in an entity, we first evaluate if we are required to apply the variable interest entity ("VIE") model to the entity, otherwise the entity is evaluated under the voting interest model. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2015. Effective April 4, 2012, Medical Billing Assistance, Inc., a Colorado corporation (“Medical Billing”), merged with and into the Company. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split. Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company. On April 2, 2012, the Company completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”). The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement. Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operating and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016, with an option by the Company to extend the term until December 31, 2023. The agreement allows the Company to hold the current or potential rights that give it the power to direct the activities of the VIE that most significantly impact the VIE's economic performance, combined with a variable interest that gives the Company the right to receive potentially significant benefits or the obligation to absorb potentially significant losses. The Company has a controlling financial interest in the VIE. Rights held by others to remove the party with power over the VIE are not considered unless one party can exercise those rights unilaterally. When changes occur to the structure of the entity, the Company will reconsider whether it is subject to the VIE model. The Company continuously evaluates whether it has a controlling financial interest in the VIE. Non-controlling interests relate to the third party ownership in a consolidated entity in which the Company has a controlling interest. For financial reporting purposes, the entity's assets, liabilities, and operations are consolidated with those of the Company, and the non-controlling interest in the entity is included in the Company's consolidated financial statements within the equity section of the consolidated Balance Sheets. The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc., TBC Holdings of Melbourne, Inc. and First Choice – Brevard, along with the VIE, The B.A.C.K. Center. All significant intercompany balances and transactions, including those involving the VIE, have been eliminated in consolidation. The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, “ Revenue Recognition ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, “ Multiple-Element Arrangements The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, “Health Care Entities” (“ASC 954-310”), significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the past history and identified trends for each of our payers. Patient Service Revenue The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Company’s patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided. Rental Revenue FCID Holdings, Inc. has one real estate holding, Marina Towers, LLC, a 78,000 95 48,698 34,480 The Company considers cash and cash equivalents to consist of cash on hand and investments having an original maturity of 90 days or less that are readily convertible into cash. As of June 30, 2015, the Company had $ 1,054,565 The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts. ⋅ Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts. ⋅ Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts. As of June 30, 2015 and December 31, 2014, the Company’s provision for bad debts was $ 1,648,785 1,482,212 Capitalized financing costs represent costs incurred in connection with obtaining the debt financing. These costs are amortized ratably and charged to financing expenses over the term of the related debt. The amortization for the three and six months ended June 30, 2015 was $ 19,229 39,915 25,466 41,372 287,091 231,369 Accounting Standards Codification subtopic “ Segment Reporting Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company's intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 286,500 4,775 9,550 0 28,650 19,100 Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 5,000 10,000 5,000 10,000 65,000 55,000 respectively. Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 39 On May 1, 2015, in connection with the operating and control agreement with Brevard Orthopaedic Spine & Pain Clinic, Inc., the Company issued 3,000,000 1.35 December 31, 2023 3,226,427 0 134.09 2.12 8.67 53,774 53,774 The Company accounts for net income (loss) per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of potentially issuable common shares such as those related to our issued convertible debt, warrants and stock options. Diluted net loss per share for three and six months ended June 30, 2015 and June 30, 2014 does not reflect the effects of 2,990,920 5,885,811 Accounting Standards Codification subtopic 825-10, “ Financial Instruments The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows. Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. As of June 30, 2015, the Company had 3,000,000 The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company owned a 0.6660 In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) Number 2015-3 entitled “Simplifying the Presentation of Debt Issuance Costs.” The new guidance specifies that debt issuance costs under the new standard are to be netted against the carrying value of the financial liability. Under current guidance, debt issuance costs are recognized as a deferred charge and reported as a separate asset on the balance sheet. The new guidance aligns the treatment of debt issuance costs and debt discounts in that both reduce the carrying value of the liability. It is important to note that neither the recognition nor measurement of debt issuance costs is changed as a result of the ASU. Amortization of debt issuance costs is to be recorded as interest expense on the income statement. The effective date of the new guidance is for fiscal years beginning after December 15, 2015, for public business entities and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been issued previously. The Company does not believe the effect of the adoption of this standard to have a material impact on the Company’s consolidated financial statements. There are other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows. The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

LIQUIDITY

LIQUIDITY	6 Months Ended
	Jun. 30, 2015
Liquidity Disclosures [Abstract]
Liquidity Disclosure [Text Block]	NOTE 2 – LIQUIDITY The Company incurred various non-recurring expenses in 2014 in connection with the planned development of its medical practice. Management believes the continuing trend of positive growth before interest, taxes, depreciation and amortization into 2015 will support improved liquidity. In the fourth quarter of 2013, the Company paid off or converted to equity a total of $ 1,238,480 On June 13, 2013, the Company’s subsidiary, First Choice – Brevard entered into a loan and security agreement with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership for an accounts receivable line of credit in the maximum aggregate amount of $ 2,000,000 12 6 100,000 1,575,000 The Company’s wholly owned subsidiary, FCID Holdings, Inc. (“FCID Holdings”) operates its real estate interests. Currently, FCID Holdings has one real estate holding, Marina Towers, LLC, a 78,000 95 48,698 34,480 The Company believes that ongoing operations of Marina Towers, LLC and the current positive cash balance along with continued execution of its business development plan will allow the Company to further improve its working capital and currently anticipates that it will have sufficient capital resources to meet projected cash flow requirements through the date that is one year and one day from the filing of this report. However, in order to execute the Company’s business development plan, which there can be no assurance it will do, the Company may need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially reduce operating expenditures. If the Company is unable to secure additional capital, it may be required to curtail its business development initiatives and take additional measures to reduce costs in order to conserve its cash.

CASH - RESTRICTED

CASH - RESTRICTED	6 Months Ended
	Jun. 30, 2015
Cash and Cash Equivalents [Abstract]
Restricted Cash and Cash Equivalents Disclosure [Text Block]	NOTE 3 — CASH – RESTRICTED Cash-restricted is comprised of funds deposited to and held by the mortgage lender for payments of property taxes, insurance, replacements and major repairs of the Company's commercial building. The majority of the restricted funds are reserved for tenant improvements. As of June 30, 2015, the Company had $372,822 in restricted cash as compared to $318,259 at December 31, 2014.

PROPERTY, PLANT, AND EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 — PROPERTY, PLANT, AND EQUIPMENT June 30, December 31, 2015 2014 Land $ 1,000,000 $ 1,000,000 Building 3,055,168 3,055,168 Building improvements 4,098,910 3,970,603 Automobiles 29,849 29,849 Computer equipment 330,776 327,847 Medical equipment 2,826,835 2,253,219 Office equipment 776,815 129,723 12,118,353 10,766,409 Less: accumulated depreciation (4,014,681) (2,472,111) $ 8,103,672 $ 8,294,298 During the three and six months ended June 30, 2015, depreciation expense charged to operations was $ 134,642 265,376 126,772 261,491

LINE OF CREDIT

LINE OF CREDIT	6 Months Ended
	Jun. 30, 2015
Line Of Credit Facility [Abstract]
Line Of Credit Facilities [Text Block]	NOTE 5 — LINE OF CREDIT Line of Credit, CT Capital On June 13, 2013, the Company’s subsidiary, First Choice – Brevard entered into a loan and security agreement (the “Loan Agreement”) with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $ 1,500,000 December 31, 2016 On November 8, 2013, in consideration for the issuance of 100,000 12 6 On June 9, 2015, First Choice – Brevard and the Lender entered into a Modification Agreement (“Modification”) further amending the Loan Agreement dated June 13, 2013, thereby increasing the Company’s accounts receivable line of credit from $ 1,500,000 2,000,000 The obligations of the Company under the Loan Agreement, as amended, are guaranteed by certain affiliates of the Company, including a personal guarantee issued by the Company’s Chief Executive Officer. As of June 30, 2015 and December 31, 2014, the outstanding balance was $ 1,575,000 1,237,000 Line of Credit, Florida Business Bank On June 27, 2012, The B.A.C.K. Center entered into a Promissory Note (the “Loan Agreement”) with Florida Business Bank, a Florida banking corporation (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $ 1,000,000 interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal, with a floor of 4.50% per annum (the “Loan”). The Loan was modified on April 9, 2013, allowing a temporary increase to $ 1,383,000 995,000 45 1,000,000 interest rate of one month Libor floating plus 2.75%, as published in The Wall Street Journal, with a floor of 2.96% per annum (2.96% at December 31, 2014 and 2013, respectively). Interest shall be due and payable monthly and principal is due on demand. The outstanding principal balance plus all accrued but unpaid interest shall be due on demand (the “Maturity Date”). Upon default, the interest may be adjusted to the highest rate permissible by law. The Loan is secured by all assets of The B.A.C.K. Center now owned or hereafter acquired. The assets constitute the collateral for the repayment of the Loan. The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 60% of Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50. As of June 30, 2015, The B.A.C.K. Center had not violated the loan covenants. The obligations of The B.A.C.K Center under the Loan Agreement are guaranteed by the shareholders of The B.A.C.K. Center. The Loan Agreement is also guaranteed in the amount of $ 950,000 899,982

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6 - CONVERTIBLE NOTES PAYABLE Hillair Capital Investments, L.P. On November 8, 2013, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Hillair Capital Investments L.P. ("Hillair") in exchange for the issuance of (i) a $ 2,320,000 8 convertible debenture, which was originally due on December 28, 2013 and subsequently extended on December 28, 2013 through November 1, 2015 2,320,000 1.35 The Debenture and the Warrant may not be converted if such conversion would result in Hillair beneficially owning in excess of 4.99% of the Company’s common stock. Hillair may waive this 4.99% restriction with 61 days’ notice to the Company. The Company issued to Hillair the Debenture with the Warrant for the net purchase price of $ 2,000,000 320,000 1.00 In connection with the issuance of the Debenture, the Company issued the Warrant, granting the holder the right to acquire an aggregate of 2,320,000 1.35 1,871,117 3.6 1.42 0 147.94 1,871,117 On January 30, 2015, the Company and Hillair entered into an Extension Agreement (“Extension”) amending the 8 580,000 In consideration of the Extension, the Company issued to Hillair 100,000 99,000 30,000 20,000 On March 15, 2015, the Company provided written notice and remitted $ 20,000 On April 9, 2015, the redemption terms of the Debenture were further modified as follows: Hillair agreed to convert $ 580,000 580,000 100,000 1.00 0.50 580,000 May 1, 2015 August 1, 2015 As a result of the modification, Hillair converted $100,000 principal amount of the Debenture, at $.50 per share, into 200,000 580,000 1.00 580,000 680,000 780,000 100,000 128,000 As of June 30, 2015, the outstanding principal amount and interest of the Debenture was $ 1,415,920 On August 3, 2015, the remaining outstanding principal balance, and accrued interest, in the aggregate amount of $ 1,161,641 the

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	NOTE 7— NOTES PAYABLE June 30, December 31, Mortgage Payable $ 7,205,024 $ 7,256,416 Note Payable, GE Capital (construction), MRI 30,869 121,204 Note Payable, GE Capital (construction), 2 15,249 44,911 Note Payable, GE Capital (MRI) 1,035,065 1,218,625 Note Payable, GE Capital (X-ray) 120,241 142,349 Note Payable, GE Arm 79,923 91,925 Note Payable, Auto 13,331 16,383 Note payable, Florida Business Bank 393,130 - Capital Lease Equipment 37,673 25,538 8,930,505 8,917,351 Less current portion (702,950) (732,791) $ 8,227,555 $ 8,184,560 Mortgage Payable On August 12, 2011, the Company refinanced its existing mortgage note payable as described below providing additional working capital funds. The aggregate amount of the note of $ 7,550,000 6.10 45,753 30 September 16, 2016 In connection with the refinancing of the mortgage note payable, the Company incurred financing costs of $ 286,723 Note Payable — Equipment Financing On May 21, 2012, the Company entered into a note payable with GE Healthcare Financial Services (“GE Capital”) in the amount of approximately $ 2.4 The Company also currently has two construction loans outstanding. As of December 2012, the construction loans are payable in 35 7.38 450,000 150,000 The Company entered into equipment finance leases for a total aggregate amount of $ 2,288,679 On September 27, 2012, the Company accepted the delivery of MRI equipment under the equipment finance lease. As such, the component piece accepted of $ 1,771,390 60 0 38,152 7.9375 11,779 38,152 On August 22, 2012, the Company accepted the delivery of X-ray equipment under the equipment finance lease. As such, the component piece accepted of $ 212,389 60 0 4,300 7.9375 1,384 4,575 On February 25, 2013, the Company accepted the delivery of C-arm equipment under the equipment finance lease. As such, the component piece accepted of $ 124,797 63 0 2,388 7.39 Note Payable — Auto On May 21, 2012, the Company issued a note payable, in the amount of $ 29,850 593 6.99 Note Payable — Florida Business Bank On June 27, 2012, The B.A.C.K. Center issued a promissory note in the aggregate amount of $ 900,931 5.50 14,753 The note was modified on April 9, 2013 requiring a principal and interest payment of $ 11,434 3.89 634,000 Capital Leases — Equipment On June 11, 2013, the Company entered into a lease agreement to acquire equipment with 48 956 June 1, 2017 14.002 On October 25, 2011, The B.A.C.K. Center entered into a lease agreement to acquire equipment with 60 monthly payments of $ 1,036 Amount Six months ended December 31, 2015 $ 404,326 Year ended December 31, 2016 7,779,410 Year ended December 31, 2017 654,891 Year ended December 31, 2018 and thereafter 91,878 Total $ 8,930,505

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Capital Stock [Text Block]	NOTE 8 — CAPITAL STOCK During the six months ended June 30, 2015, the Company issued an aggregate of 200,000 During the six months ended June 30, 2015, the Company issued an aggregate of 811,200 780,000 31,200 During the six months ended June 30, 2015, the Company issued an aggregate of 506,000 530,000 221,000 Stock-Based Payable The Company is obligated to issue an aggregate of 147,500 147,500 1.00 537,750 1.32

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Warrants Disclosure [Text Block]	NOTE 9 — STOCK OPTIONS AND WARRANTS Warrants Warrants Outstanding Warrants Exercisable Price Outstanding Expiration Date Weighted Exercisable Weighted $ 1.35 2,320,000 November 8, 2018 $ 1.35 2,320,000 $ 1.35 $ 3.60 1,875,000 December 31, 2016 $ 3.60 1,875,000 $ 3.60 4,195,000 $ 2.36 4,195,000 $ 2.36 The warrant to purchase up to 2,320,000 1,875,000 Number of Weighted Outstanding at December 31, 2013: 4,195,000 $ 2.36 Granted - - Exercised - - Expired - - Outstanding at December 31, 2014: 4,195,000 $ 2.36 Granted - - Exercised - - Expired - - Outstanding at June 30,2015 4,195,000 $ 2.36 Options Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2015 - $ - - $ - Granted 3,000,000 1.35 8.67 - Canceled/expired - - - - Outstanding at June 30, 2015 3,000,000 $ 1.35 8.50 $ - Exercisable at June 30, 2015 - $ - - $ - Options Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $1.35 3,000,000 8.50 - On May 1, 2015, in connection with the Operating and Control Agreement with Brevard Orthopaedic Spine & Pain Clinic, Inc., the Company issued 3,000,000 1.35 contingent on the variable interest entity (VIE), The B.A.C.K. Center, being acquired by the Company and The B.A.C.K. Center employees executing employment contracts with TBC Holdings. 3,226,427 0 134.09 2.12 8.67 life; and is recorded as deferred costs and amortized over the contract term of the Operating and Control Agreement of the VIE

VARIABLE INTEREST ENTITY

VARIABLE INTEREST ENTITY	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entity Disclosure [Text Block]	NOTE 10 — VARIABLE INTEREST ENTITY Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc. entered into an Operating and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations including the requirement to absorb losses or right to receive economic benefits The initial term of the Agreement expires on December 31, 2016, with an option by the Company to extend the term until December 31, 2023. The Company issued 3,000,000 vesting contingent on The B.A.C.K. Center employees signing employment contracts with TBD Holdings and the variable interest entity, The B.A.C.K. Center, being acquired by the Company 1.35 The Company has determined that The B.A.C.K. Center is a Variable Interest Entity ("VIE") in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 810, "Consolidation". In determining whether the Company has the right to receive benefits or the obligation to absorb losses that could potentially be significant to the VIE, the Company evaluates all of its economic interests in the entity, regardless of form (debt, equity, management and servicing fees, and other contractual arrangements). This evaluation considers all relevant factors of the entity's structure, including: the entity's capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. The evaluation of each of these factors in reaching a conclusion about the potential significance of the Company's economic interests is a matter that requires the exercise of professional judgment. Current assets: Cash $ 999,128 Accounts receivable 2,038,218 Due from First Choice Healthcare Solutions 25,368 Other current assets 632,853 Total current assets 3,695,567 Property and equipment, net 31,463 Other assets 23,026 Total assets $ 3,750,056 Current liabilities: Accounts payable and accrued liabilities $ 970,626 Other current liabilities 1,086,469 Total current liabilities 2,057,095 Long term debt 1,831,647 Total liabilities 3,888,742 Deficit (138,686) Total liabilities and deficit $ 3,750,056 Total revenues from The B.A.C.K. Center were $ 2,206,102 1,250,618 969,706 3,223 7,923

SEGMENT REPORTING

SEGMENT REPORTING	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	NOTE 11 — SEGMENT REPORTING The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company's reportable segments. The Company has three reportable segments: Marina Towers, LLC, FCID Medical, Inc. and The B.A.C.K Center. The Marina Towers, LLC segment derives revenue from the operating leases of its owned building, FCID Medical segment derives revenue for medical services provided to patients, and The B.A.C.K Center derives revenue for subleasing space within its building and medical services provided to patients. Information concerning the operations of the Company's reportable segments is as follows: Marina FCID Brevard Intercompany Towers Medical Orthopedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 1,873,219 $ 1,930,820 $ - $ - $ 3,804,039 Rental revenue 375,512 - 256,132 - (111,368) 520,276 Total Revenue 375,512 1,873,219 2,186,952 - (111,368) 4,324,315 Operating expenses: Salaries & benefits 3,000 781,064 1,250,618 90,799 - 2,125,481 Other operating expenses 109,943 564,847 - - (111,368) 563,422 General and administrative 24,148 319,237 917,456 389,029 - 1,649,870 Depreciation and amortization 69,674 66,745 3,223 4,775 - 144,417 Total operating expenses 206,765 1,731,893 2,171,297 484,603 (111,368) 4,483,190 Net income (loss) from operations: 168,747 141,326 15,655 (484,603) - (158,875) Interest expense (109,300) (68,798) (7,264) (173,632) - (358,994) Amortization of financing costs (14,337) (4,233) (659) - - (19,229) Other income (expense) 21,219 - 19,150 - - 40,369 Net Income (loss): 66,329 68,295 26,882 (658,235) - (496,729) Income taxes - - - - - - Net income (loss) $ 66,329 $ 68,295 $ 26,882 $ (658,235) $ - $ (496,729) Summary Statement of Operations for the three months ended June 30, 2014: Marina FCID Brevard Intercompany Towers Medical Orthopedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 1,848,441 $ - $ - $ - $ 1,848,441 Rental revenue 367,460 - - - (108,737) 258,723 Total Revenue 367,460 1,848,441 - - (108,737) 2,107,164 Operating expenses: Salaries & benefits 3,000 996,555 - 91,251 - 1,090,806 Other operating expenses 109,989 425,804 - - (108,737) 427,056 General and administrative 21,903 328,909 - 318,396 - 669,208 Depreciation and amortization 69,219 57,553 - - - 126,772 Total operating expenses 204,111 1,808,821 - 409,647 (108,737) 2,313,842 Net income (loss) from operations: 163,349 39,620 - (409,647) - (206,678) Interest expense (114,067) (55,951) - (47,159) - (217,177) Amortization of financing costs (14,337) (11,129) - - - (25,466) Other income (expense) 750 - - - - 750 Net Income (loss): 35,695 (27,460) - (456,806) - (448,571) Income taxes - - - - - - Net income (loss) $ 35,695 $ (27,460) $ - $ (456,806) $ - $ (448,571) Summary Statement of Operations for the six months ended June 30, 2015: Marina FCID Brevard Intercompany Towers Medical Orthopedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 4,113,283 $ 1,930,820 $ - $ - $ 6,044,103 Rental revenue 750,833 - 256,132 - (221,586) 785,379 Total Revenue 750,833 4,113,283 2,186,952 - (221,586) 6,829,482 Operating expenses: Salaries & benefits 6,000 1,618,051 1,250,618 196,932 - 3,071,601 Other operating expenses 213,274 1,023,219 - - (221,586) 1,014,907 General and administrative 46,790 610,396 917,456 628,512 - 2,203,154 Depreciation and amortization 138,893 133,260 3,223 9,550 - 284,926 Total operating expenses 404,957 3,384,926 2,171,297 834,994 (221,586) 6,574,588 Net income (loss) from operations: 345,876 728,357 15,655 (834,994) - 254,894 Interest expense (219,796) (120,582) (7,264) (374,496) - (722,138) Amortization of financing costs (28,674) (10,582) (659) - - (39,915) Other income (expense) 21,969 - 19,150 - - 41,119 Net Income (loss): 119,375 597,193 26,882 (1,209,490) - (466,040) Income taxes - - - - - Net income (loss) $ 119,375 $ 597,193 $ 26,882 $ (1,209,490) $ - $ (466,040) Summary Statement of Operations for the six months ended June 30, 2014: Marina FCID Brevard Intercompany Towers Medical Orthopaedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 3,821,271 $ - $ - $ - $ 3,821,271 Rental revenue 736,971 - - - (216,325) 520,646 Total Revenue 736,971 3,821,271 - - (216,325) 4,341,917 Operating expenses: Salaries & benefits 6,000 1,976,438 - 173,889 - 2,156,327 Other operating expenses 213,601 859,071 - - (216,325) 856,347 General and administrative 43,722 565,161 - 466,237 - 1,075,120 Depreciation and amortization 138,228 123,263 - - - 261,491 Total operating expenses 401,551 3,523,933 - 640,126 (216,325) 4,349,285 Net income (loss) from operations: 335,420 297,338 - (640,126) - (7,368) Interest expense (226,091) (115,288) - (95,051) - (436,430) Amortization of financing costs (28,674) (12,698) - - - (41,372) Other income (expense) 1,500 - - - - 1,500 Net Income (loss): 82,155 169,352 - (735,177) - (483,670) Income taxes - - - - - - Net income (loss) $ 82,155 $ 169,352 $ - $ (735,177) $ - $ (483,670) Marina FCID Brevard Intercompany Towers Medical Orthopaedic Corporate Eliminations Total Assets: At June 30, 2015: $ 6,508,932 $ 4,873,844 $ 3,724,688 $ 3,480,083 $ - $ 18,587,547 At December 31, 2014: $ 6,726,759 $ 4,407,749 $ - $ 336,184 $ - $ 11,470,692 Assets acquired Three month ended June 30, 2015: $ 29,781 $ 1,999 $ - $ - $ - $ 31,780 Three months ended June 30, 2014: $ 6,319 $ 70,665 $ - $ - $ - $ 76,984 Six months ended June 30, 2015: $ 36,409 $ 3,656 $ - $ - $ - $ 40,065 Six months ended June 30, 2014: $ 16,758 $ 71,224 $ - $ - $ - $ 87,982

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 12 - COMMITMENTS AND CONTINGENCIES Litigation On or about July 25, 2014, MedTRX Health Care Solutions, LLC and MedTRX Collection Services, LLC (“MedTRX”) filed a demand for arbitration with the American Arbitration Association (“AAA”) against FCID Medical, Inc. and First Choice Medical Group of Brevard, LLC (collectively, “First Choice”). MedTRX claims that First Choice breached an exclusive five-year billing and collection agreement, dated December 9, 2011, (“Billing Agreement”) by engaging another billing service on or about June 1, 2014. MedTRX also claims that First Choice failed to pay for services that MedTRX had performed prior to June 1, 2014, leaving a balance due of $93,280.84. MedTRX claims total damages of “not less than $ 3 The B.A.C.K. Center has a claim filed in Brevard County, Florida Circuit Court against Health First Management, Inc. due to a contract dispute. A counterclaim was filed against the Company. The case has been litigated for a substantial amount of time and a trial is anticipated to take place within the next twelve months. The Company has vigorously defended against the counterclaim. The Company has accrued a possible loss contingency of approximately $ 118,000 From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Operating Leases The B.A.C.K. Center leases office space under various non-cancelable operating leases that expire at various dates through June 2026. Terms of the lease agreements provide for rental payments ranging from approximately $ 4,200 200,000 260,234 Six months ended December 31 2015: $ 1,732,268 Year ended December 31, 2016 3,494,547 Year ended December 31, 2017 3,444,197 Year ended December 31, 2018 3,444,209 Year ended December 31, 2019 3,444,221 $ 15,559,442 Guarantees Two of The B.A.C.K. Center’s shareholders and a related party have guaranteed the full and prompt payment of the base rent, the additional rent and any all other sums and charges payable by a tenant, its successors and assigns under the lease, and the full performance and observance of all the covenants, terms, conditions and agreements for one of the above mentioned operating leases.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS Hillair Capital Investments, L.P. On August 3, 2015, the remaining outstanding principal balance and accrued interest in the aggregate amount of $ 1,161,641 8 November 1, 2015 L.P. was 1.00 1,161,641

SIGNIFICANT ACCOUNTING POLICI20

SIGNIFICANT ACCOUNTING POLICIES; BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Effective April 4, 2012, Medical Billing Assistance, Inc., a Colorado corporation (“Medical Billing”), merged with and into the Company. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split. Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company. On April 2, 2012, the Company completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”). The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement. Effective May 1, 2015, the Company, through its recently formed wholly owned subsidiary, TBC Holdings of Melbourne, Inc., entered into an Operating and Control Agreement (the Agreement”) with Brevard Orthopaedic Spine & Pain Clinic, Inc. (“The B.A.C.K. Center”), whereby the Company will have sole and exclusive management and control of The B.A.C.K. Center, including, but not limited to, administrative, financial, facility and business operations, including the requirement to absorb losses or right to receive economic benefits. The initial term of the Agreement expires on December 31, 2016, with an option by the Company to extend the term until December 31, 2023. The agreement allows the Company to hold the current or potential rights that give it the power to direct the activities of the VIE that most significantly impact the VIE's economic performance, combined with a variable interest that gives the Company the right to receive potentially significant benefits or the obligation to absorb potentially significant losses. The Company has a controlling financial interest in the VIE. Rights held by others to remove the party with power over the VIE are not considered unless one party can exercise those rights unilaterally. When changes occur to the structure of the entity, the Company will reconsider whether it is subject to the VIE model. The Company continuously evaluates whether it has a controlling financial interest in the VIE. Non-controlling interests relate to the third party ownership in a consolidated entity in which the Company has a controlling interest. For financial reporting purposes, the entity's assets, liabilities, and operations are consolidated with those of the Company, and the non-controlling interest in the entity is included in the Company's consolidated financial statements within the equity section of the consolidated Balance Sheets. The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc., TBC Holdings of Melbourne, Inc. and First Choice – Brevard, along with the VIE, The B.A.C.K. Center. All significant intercompany balances and transactions, including those involving the VIE, have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, “ Revenue Recognition ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, “ Multiple-Element Arrangements The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, “Health Care Entities” (“ASC 954-310”), significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the past history and identified trends for each of our payers. Patient Service Revenue The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Company’s patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided. Rental Revenue FCID Holdings, Inc. has one real estate holding, Marina Towers, LLC, a 78,000 95 48,698 34,480
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers cash and cash equivalents to consist of cash on hand and investments having an original maturity of 90 days or less that are readily convertible into cash. As of June 30, 2015, the Company had $ 1,054,565
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts. ⋅ Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts. ⋅ Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts. As of June 30, 2015 and December 31, 2014, the Company’s provision for bad debts was $ 1,648,785 1,482,212
Capitalized Financing Cost [Policy Text Block]	Capitalized Financing Costs Capitalized financing costs represent costs incurred in connection with obtaining the debt financing. These costs are amortized ratably and charged to financing expenses over the term of the related debt. The amortization for the three and six months ended June 30, 2015 was $ 19,229 39,915 25,466 41,372 287,091 231,369
Segment Reporting, Policy [Policy Text Block]	Segment Information Accounting Standards Codification subtopic “ Segment Reporting
Patents [Policy Text Block]	Patents Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company's intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 286,500 4,775 9,550 0 28,650 19,100
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Patient list is comprised of acquired patients in connection with the acquisition of First Choice - Brevard and is amortized ratably over the estimated useful life of 15 5,000 10,000 5,000 10,000 65,000 55,000 respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 39
Deferred Costss, Policy [Policy Text Block]	Deferred costs On May 1, 2015, in connection with the operating and control agreement with Brevard Orthopaedic Spine & Pain Clinic, Inc., the Company issued 3,000,000 1.35 December 31, 2023 3,226,427 0 134.09 2.12 8.67 53,774 53,774
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) Per Share The Company accounts for net income (loss) per share in accordance with Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS. Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of potentially issuable common shares such as those related to our issued convertible debt, warrants and stock options. Diluted net loss per share for three and six months ended June 30, 2015 and June 30, 2014 does not reflect the effects of 2,990,920 5,885,811
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, “ Financial Instruments The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. As of June 30, 2015, the Company had 3,000,000
Inventory, Policy [Policy Text Block]	Investments The Company has adopted Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company owned a 0.6660
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) Number 2015-3 entitled “Simplifying the Presentation of Debt Issuance Costs.” The new guidance specifies that debt issuance costs under the new standard are to be netted against the carrying value of the financial liability. Under current guidance, debt issuance costs are recognized as a deferred charge and reported as a separate asset on the balance sheet. The new guidance aligns the treatment of debt issuance costs and debt discounts in that both reduce the carrying value of the liability. It is important to note that neither the recognition nor measurement of debt issuance costs is changed as a result of the ASU. Amortization of debt issuance costs is to be recorded as interest expense on the income statement. The effective date of the new guidance is for fiscal years beginning after December 15, 2015, for public business entities and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been issued previously. The Company does not believe the effect of the adoption of this standard to have a material impact on the Company’s consolidated financial statements. There are other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

PROPERTY, PLANT, AND EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant and equipment at June 30, 2015 and December 31, 2014 are as follows: June 30, December 31, 2015 2014 Land $ 1,000,000 $ 1,000,000 Building 3,055,168 3,055,168 Building improvements 4,098,910 3,970,603 Automobiles 29,849 29,849 Computer equipment 330,776 327,847 Medical equipment 2,826,835 2,253,219 Office equipment 776,815 129,723 12,118,353 10,766,409 Less: accumulated depreciation (4,014,681) (2,472,111) $ 8,103,672 $ 8,294,298

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Notes payable as of June 30, 2015 and December 31, 2014 are comprised of the following: June 30, December 31, Mortgage Payable $ 7,205,024 $ 7,256,416 Note Payable, GE Capital (construction), MRI 30,869 121,204 Note Payable, GE Capital (construction), 2 15,249 44,911 Note Payable, GE Capital (MRI) 1,035,065 1,218,625 Note Payable, GE Capital (X-ray) 120,241 142,349 Note Payable, GE Arm 79,923 91,925 Note Payable, Auto 13,331 16,383 Note payable, Florida Business Bank 393,130 - Capital Lease Equipment 37,673 25,538 8,930,505 8,917,351 Less current portion (702,950) (732,791) $ 8,227,555 $ 8,184,560
Schedule of Maturities of Long-term Debt [Table Text Block]	Aggregate Principal Maturities of Long-Term Debt as of June 30, 2015 Amount Six months ended December 31, 2015 $ 404,326 Year ended December 31, 2016 7,779,410 Year ended December 31, 2017 654,891 Year ended December 31, 2018 and thereafter 91,878 Total $ 8,930,505

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Warrants Outstanding And Related Exercise Prices [Table Text Block]	The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company's common stock as of June 30, 2015: Warrants Outstanding Warrants Exercisable Price Outstanding Expiration Date Weighted Exercisable Weighted $ 1.35 2,320,000 November 8, 2018 $ 1.35 2,320,000 $ 1.35 $ 3.60 1,875,000 December 31, 2016 $ 3.60 1,875,000 $ 3.60 4,195,000 $ 2.36 4,195,000 $ 2.36
Schedule of Transactions Involving Stock Warrants Issued To Non-employees [Table Text Block]	Transactions involving stock warrants issued to non-employees are summarized as follows: Number of Weighted Outstanding at December 31, 2013: 4,195,000 $ 2.36 Granted - - Exercised - - Expired - - Outstanding at December 31, 2014: 4,195,000 $ 2.36 Granted - - Exercised - - Expired - - Outstanding at June 30,2015 4,195,000 $ 2.36
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes the stock option activity for the six months ended June 30, 2015: Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2015 - $ - - $ - Granted 3,000,000 1.35 8.67 - Canceled/expired - - - - Outstanding at June 30, 2015 3,000,000 $ 1.35 8.50 $ - Exercisable at June 30, 2015 - $ - - $ -
Schedule of Stock Options Information [Table Text Block]	The following table presents information related to stock options at June 30, 2015: Options Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $1.35 3,000,000 8.50 -

VARIABLE INTEREST ENTITY (Table

VARIABLE INTEREST ENTITY (Table)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities [Table Text Block]	The table below summarizes the assets and liabilities associated with The B.A.C.K. Center as of June 30, 2015: Current assets: Cash $ 999,128 Accounts receivable 2,038,218 Due from First Choice Healthcare Solutions 25,368 Other current assets 632,853 Total current assets 3,695,567 Property and equipment, net 31,463 Other assets 23,026 Total assets $ 3,750,056 Current liabilities: Accounts payable and accrued liabilities $ 970,626 Other current liabilities 1,086,469 Total current liabilities 2,057,095 Long term debt 1,831,647 Total liabilities 3,888,742 Deficit (138,686) Total liabilities and deficit $ 3,750,056

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Summary Statement of Operations for the three months ended June 30, 2015: Marina FCID Brevard Intercompany Towers Medical Orthopedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 1,873,219 $ 1,930,820 $ - $ - $ 3,804,039 Rental revenue 375,512 - 256,132 - (111,368) 520,276 Total Revenue 375,512 1,873,219 2,186,952 - (111,368) 4,324,315 Operating expenses: Salaries & benefits 3,000 781,064 1,250,618 90,799 - 2,125,481 Other operating expenses 109,943 564,847 - - (111,368) 563,422 General and administrative 24,148 319,237 917,456 389,029 - 1,649,870 Depreciation and amortization 69,674 66,745 3,223 4,775 - 144,417 Total operating expenses 206,765 1,731,893 2,171,297 484,603 (111,368) 4,483,190 Net income (loss) from operations: 168,747 141,326 15,655 (484,603) - (158,875) Interest expense (109,300) (68,798) (7,264) (173,632) - (358,994) Amortization of financing costs (14,337) (4,233) (659) - - (19,229) Other income (expense) 21,219 - 19,150 - - 40,369 Net Income (loss): 66,329 68,295 26,882 (658,235) - (496,729) Income taxes - - - - - - Net income (loss) $ 66,329 $ 68,295 $ 26,882 $ (658,235) $ - $ (496,729) Summary Statement of Operations for the three months ended June 30, 2014: Marina FCID Brevard Intercompany Towers Medical Orthopedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 1,848,441 $ - $ - $ - $ 1,848,441 Rental revenue 367,460 - - - (108,737) 258,723 Total Revenue 367,460 1,848,441 - - (108,737) 2,107,164 Operating expenses: Salaries & benefits 3,000 996,555 - 91,251 - 1,090,806 Other operating expenses 109,989 425,804 - - (108,737) 427,056 General and administrative 21,903 328,909 - 318,396 - 669,208 Depreciation and amortization 69,219 57,553 - - - 126,772 Total operating expenses 204,111 1,808,821 - 409,647 (108,737) 2,313,842 Net income (loss) from operations: 163,349 39,620 - (409,647) - (206,678) Interest expense (114,067) (55,951) - (47,159) - (217,177) Amortization of financing costs (14,337) (11,129) - - - (25,466) Other income (expense) 750 - - - - 750 Net Income (loss): 35,695 (27,460) - (456,806) - (448,571) Income taxes - - - - - - Net income (loss) $ 35,695 $ (27,460) $ - $ (456,806) $ - $ (448,571) Summary Statement of Operations for the six months ended June 30, 2015: Marina FCID Brevard Intercompany Towers Medical Orthopedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 4,113,283 $ 1,930,820 $ - $ - $ 6,044,103 Rental revenue 750,833 - 256,132 - (221,586) 785,379 Total Revenue 750,833 4,113,283 2,186,952 - (221,586) 6,829,482 Operating expenses: Salaries & benefits 6,000 1,618,051 1,250,618 196,932 - 3,071,601 Other operating expenses 213,274 1,023,219 - - (221,586) 1,014,907 General and administrative 46,790 610,396 917,456 628,512 - 2,203,154 Depreciation and amortization 138,893 133,260 3,223 9,550 - 284,926 Total operating expenses 404,957 3,384,926 2,171,297 834,994 (221,586) 6,574,588 Net income (loss) from operations: 345,876 728,357 15,655 (834,994) - 254,894 Interest expense (219,796) (120,582) (7,264) (374,496) - (722,138) Amortization of financing costs (28,674) (10,582) (659) - - (39,915) Other income (expense) 21,969 - 19,150 - - 41,119 Net Income (loss): 119,375 597,193 26,882 (1,209,490) - (466,040) Income taxes - - - - - Net income (loss) $ 119,375 $ 597,193 $ 26,882 $ (1,209,490) $ - $ (466,040) Summary Statement of Operations for the six months ended June 30, 2014: Marina FCID Brevard Intercompany Towers Medical Orthopaedic Corporate Eliminations Total Revenue: Net Patient Service Revenue $ - $ 3,821,271 $ - $ - $ - $ 3,821,271 Rental revenue 736,971 - - - (216,325) 520,646 Total Revenue 736,971 3,821,271 - - (216,325) 4,341,917 Operating expenses: Salaries & benefits 6,000 1,976,438 - 173,889 - 2,156,327 Other operating expenses 213,601 859,071 - - (216,325) 856,347 General and administrative 43,722 565,161 - 466,237 - 1,075,120 Depreciation and amortization 138,228 123,263 - - - 261,491 Total operating expenses 401,551 3,523,933 - 640,126 (216,325) 4,349,285 Net income (loss) from operations: 335,420 297,338 - (640,126) - (7,368) Interest expense (226,091) (115,288) - (95,051) - (436,430) Amortization of financing costs (28,674) (12,698) - - - (41,372) Other income (expense) 1,500 - - - - 1,500 Net Income (loss): 82,155 169,352 - (735,177) - (483,670) Income taxes - - - - - - Net income (loss) $ 82,155 $ 169,352 $ - $ (735,177) $ - $ (483,670) Marina FCID Brevard Intercompany Towers Medical Orthopaedic Corporate Eliminations Total Assets: At June 30, 2015: $ 6,508,932 $ 4,873,844 $ 3,724,688 $ 3,480,083 $ - $ 18,587,547 At December 31, 2014: $ 6,726,759 $ 4,407,749 $ - $ 336,184 $ - $ 11,470,692 Assets acquired Three month ended June 30, 2015: $ 29,781 $ 1,999 $ - $ - $ - $ 31,780 Three months ended June 30, 2014: $ 6,319 $ 70,665 $ - $ - $ - $ 76,984 Six months ended June 30, 2015: $ 36,409 $ 3,656 $ - $ - $ - $ 40,065 Six months ended June 30, 2014: $ 16,758 $ 71,224 $ - $ - $ - $ 87,982

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next five years ending December 31 and thereafter: Six months ended December 31 2015: $ 1,732,268 Year ended December 31, 2016 3,494,547 Year ended December 31, 2017 3,444,197 Year ended December 31, 2018 3,444,209 Year ended December 31, 2019 3,444,221 $ 15,559,442

SIGNIFICANT ACCOUNTING POLICI27

SIGNIFICANT ACCOUNTING POLICIES; BASIS OF PRESENTATION (Details Textual)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May. 31, 2015USD ($)ft²$ / sharesshares	Jun. 30, 2015USD ($)ft²a	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)ft²ashares	Jun. 30, 2014USD ($)shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)shares
Summary of Significant Accounting Policies [Line Items]
Amortization Financing Costs		$ 19,229	$ 25,466	$ 39,915	$ 41,372
Investment Maturity Term				90 days or less
Accumulated Amortization, Deferred Finance Costs		287,091		$ 287,091		$ 231,369
Allowance for Doubtful Accounts Receivable		1,648,785		$ 1,648,785		1,482,212
Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount | shares				2,990,920	5,885,811
Cash and Cash Equivalents, at Carrying Value, Total		1,054,565	70,812	$ 1,054,565	$ 70,812	279,087	$ 739,158
Finite-Lived Intangible Assets, Accumulated Amortization		65,000		$ 65,000		55,000
Finite-Lived Intangible Asset, Useful Life				15 years
Adjustments to Additional Paid in Capital, Fair Value				$ 3,226,427	0
Amortization of Deferred Charges, Total		53,774		53,774		0
Accumulated Amortization of Other Deferred Costs		$ 53,774		$ 53,774
Third Party Tenants [Member]
Summary of Significant Accounting Policies [Line Items]
Land Subject to Ground Leases | a		48,698		48,698
Doctor’s Surgical Partnership, LTD [Member]
Summary of Significant Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage		0.666%		0.666%
TBC Holdings of Melbourne, Inc [Member]
Summary of Significant Accounting Policies [Line Items]
Area of Land | ft²	34,480
Brevard Orthopaedic Spine Pain Clinic, Inc. [Member]
Summary of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues | shares	3,000,000
Share Price | $ / shares	$ 1.35
Adjustments to Additional Paid in Capital, Fair Value	$ 3,226,427
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	134.09%
Fair Value Assumptions, Risk Free Interest Rate	2.12%
Fair Value Assumptions, Expected Term	8 years 8 months 1 day
Options Expiration Date	Dec. 31, 2023
Marina Towers LLC [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization Financing Costs		$ 14,337	14,337	$ 28,674	28,674
Area of Land, Percentage of Occupancy				95.00%
Area of Land | ft²		78,000		78,000
Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, Purchase of Assets | shares							636,666
Stock Issued During Period, Value, Purchase of Assets							$ 286,500
Adjustments to Additional Paid in Capital, Fair Value				$ 0
Patient Lists [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization of Intangible Assets		$ 5,000	5,000	10,000	10,000
Finite-Lived Intangible Assets, Accumulated Amortization		65,000		65,000		55,000
Patents [Member]
Summary of Significant Accounting Policies [Line Items]
Amortization of Intangible Assets		4,775	$ 0	9,550	$ 0
Finite-Lived Intangible Assets, Accumulated Amortization		$ 28,650		$ 28,650		$ 19,100
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life				39 years
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life				5 years

LIQUIDITY (Details Textual)

LIQUIDITY (Details Textual)	Nov. 08, 2013shares	Jun. 13, 2013USD ($)shares	Dec. 31, 2013USD ($)	Jun. 30, 2015USD ($)ft²a	Jun. 09, 2015USD ($)	May. 31, 2015ft²	Dec. 31, 2014USD ($)
Liquidity Disclosures [Line Items]
Long-term Line of Credit		$ 2,000,000		$ 1,575,000			$ 1,237,000
Line of Credit, Current				2,474,982			$ 1,237,000
Debt Conversion, Converted Instrument, Amount			$ 1,238,480	$ 811,200
Accounts Receivable [Member] | Minimum [Member]
Liquidity Disclosures [Line Items]
Long-term Line of Credit					$ 1,500,000
Accounts Receivable [Member] | Maximum [Member]
Liquidity Disclosures [Line Items]
Long-term Line of Credit					$ 2,000,000
Marina Towers LLC [Member]
Liquidity Disclosures [Line Items]
Area of Land, Percentage of Occupancy				95.00%
Area of Land | ft²				78,000
CT Capital LTD [Member]
Liquidity Disclosures [Line Items]
Debt Instrument, Interest Rate During Period	12.00%	12.00%
Debt Instrument, Interest Rate, Effective Percentage	6.00%	6.00%
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total | shares	100,000	100,000
Line of Credit, Current				$ 1,575,000
Third Party Tenants [Member]
Liquidity Disclosures [Line Items]
Land Subject to Ground Leases | a				48,698
TBC Holdings of Melbourne, Inc [Member]
Liquidity Disclosures [Line Items]
Area of Land | ft²						34,480

CASH - RESTRICTED (Details Text

CASH - RESTRICTED (Details Textual) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted Cash and Cash Equivalents	$ 372,822	$ 318,259

PROPERTY, PLANT, AND EQUIPMEN30

PROPERTY, PLANT, AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 12,118,353	$ 10,766,409
Less: accumulated depreciation	(4,014,681)	(2,472,111)
Property, plant and equipment, net	8,103,672	8,294,298
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,000,000	1,000,000
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	3,055,168	3,055,168
Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	4,098,910	3,970,603
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	29,849	29,849
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	330,776	327,847
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,826,835	2,253,219
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 776,815	$ 129,723

PROPERTY, PLANT, AND EQUIPMEN31

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$ 134,642	$ 126,772	$ 265,376	$ 261,491

LINE OF CREDIT (Details Textual

LINE OF CREDIT (Details Textual) - Range [Domain] - USD ($)	Nov. 08, 2013	Jun. 13, 2013	Jun. 27, 2012	Jun. 30, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Line Of Credit Facility, Expiration Date		Dec. 31, 2016
Line Of Credit Facility, Amount Outstanding		$ 2,000,000		$ 1,575,000	$ 1,237,000
Line of Credit, Florida Business Bank [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Covenant Terms			The advance rate is defined as: 60% of Medicare and Medicaid receivables less than 90 days old multiplied by a factor of 0.25, plus all other receivables less than 90 days old multiplied by a factor of 0.50. As of June 30, 2015, The B.A.C.K. Center had not violated the loan covenants.
Line Of Credit Guaranteed Amount				950,000
Line of Credit Facility, Average Outstanding Amount				$ 899,982
TBC Equipment Leasing, LLC member [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate Description			interest rate of one month Libor floating plus 2.75%, as published in The Wall Street Journal, with a floor of 2.96% per annum (2.96% at December 31, 2014 and 2013, respectively).
Line of Credit Facility, Increase (Decrease), Net, Total			$ 1,383,000
Line of Credit Facility, Increase (Decrease), Other, Net			$ 995,000
Debt Instrument, Term			45 days
Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases			$ 1,000,000
Accounts Receivable [Member] | Line of Credit, Florida Business Bank [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,000,000
Line of Credit Facility, Interest Rate Description				interest rate of Prime floating plus 1.0%, as published in The Wall Street Journal, with a floor of 4.50% per annum (the Loan).
Line of Credit, CT Capital [Member]
Line of Credit Facility [Line Items]
Short-term Debt, Maximum Amount Outstanding During Period		$ 1,500,000
Line of Credit Facility, Collateral		The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection.
Debt Instrument, Convertible, Terms of Conversion Feature		At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share.
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total	100,000	100,000
Debt Instrument, Interest Rate During Period	12.00%	12.00%
Debt Instrument, Interest Rate, Effective Percentage	6.00%	6.00%

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Textual) - USD ($)	Apr. 09, 2015	Nov. 08, 2013	Jan. 30, 2015	Dec. 31, 2013	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2013	Aug. 03, 2015	Mar. 15, 2015
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Principal			$ 580,000
Debt Instrument, Maturity Date, Description					convertible debenture, which was originally due on December 28, 2013 and subsequently extended on December 28, 2013 through November 1, 2015
Debt Conversion, Description					The Debenture and the Warrant may not be converted if such conversion would result in Hillair beneficially owning in excess of 4.99% of the Companys common stock. Hillair may waive this 4.99% restriction with 61 days notice to the Company.
Debt Conversion, Original Debt, Amount					$ 811,200	$ 208,700
Amortization of Debt Discount (Premium)							$ 1,871,117
Debt Conversion, Converted Instrument, Amount				$ 1,238,480	$ 811,200
Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					811,200
Debt Conversion, Converted Instrument, Amount					$ 811
Hillair Extension Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 1
Debt Instrument, Periodic Payment, Principal	$ 580,000
Interest Expense, Debt	$ 128,000
Debt Conversion, Converted Instrument, Shares Issued	580,000
Repayments of Convertible Debt			$ 30,000
Stock Issued During Period, Shares, New Issues	100,000		100,000
Stock Issued During Period, Value, New Issues			$ 99,000
Debt Issuance Cost			$ 20,000
Debt Instrument, Maturity Date	Aug. 1, 2015
Hillair Extension Agreement [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues	200,000
Hillair Capital Investments L P [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%	8.00%
Debt Instrument, Face Amount	$ 580,000	$ 2,320,000							$ 20,000
Proceeds From Convertible Debt							$ 2,000,000
Fair Value Assumptions, Expected Dividend Rate							0.00%
Fair Value Assumptions, Risk Free Interest Rate							1.42%
Fair Value Assumptions, Expected Volatility Rate							147.94%
Fair Value Assumptions, Expected Term							3 years 7 months 6 days
Warrants Issued, Number of Warrants		2,320,000
Warrants Issued, Exercise Price		$ 1.35
Debt Instrument, Convertible, Conversion Price				$ 1			$ 1
Debt Instrument, Unamortized Discount				$ 320,000			$ 320,000
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature		$ 1,871,117
Debt Conversion, Original Debt, Amount	$ 100,000
Debt Conversion, Converted Instrument, Shares Issued	580,000
Debt Conversion, Converted Instrument, Amount	$ 580,000
Debt Instrument, Maturity Date	May 1, 2015
Hillair Capital Investments L P [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Convertible Debt, Current								$ 1,161,641
Maximum [Member] | Hillair Capital Investments L P [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 1
Minimum [Member] | Hillair Capital Investments L P [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	0.50
Debenture [Member] | Hillair Extension Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 0.50
Debt Conversion, Original Debt, Amount	$ 680,000
Debt Conversion, Converted Instrument, Shares Issued	780,000
Debenture [Member] | Hillair Capital Investments L P [Member]
Debt Instrument [Line Items]
Warrants Issued, Number of Warrants		2,320,000
Warrants Issued, Exercise Price		$ 1.35
Interest Expense, Debt					$ 1,415,920

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Notes Payable	$ 8,930,505	$ 8,917,351
Less: current portion	(702,950)	(732,791)
Notes payable, long term portion	8,227,555	8,184,560
Mortgage payable [Member]
Debt Instrument [Line Items]
Notes Payable	7,205,024	7,256,416
Note Payable, GE Capital (construction), MRI [Member]
Debt Instrument [Line Items]
Notes Payable	30,869	121,204
Note Payable, GE Capital (construction), 2 [Member]
Debt Instrument [Line Items]
Notes Payable	15,249	44,911
Note Payable, GE Capital (MRI) [Member]
Debt Instrument [Line Items]
Notes Payable	1,035,065	1,218,625
Note Payable GE Capital (X-Ray) [Member]
Debt Instrument [Line Items]
Notes Payable	120,241	142,349
Note Payable GE Arm [Member]
Debt Instrument [Line Items]
Notes Payable	79,923	91,925
Note Payable Auto [Member]
Debt Instrument [Line Items]
Notes Payable	13,331	16,383
Note payable, Florida Business Bank [Member]
Debt Instrument [Line Items]
Notes Payable	393,130	0
Capital Lease Equipment [Member]
Debt Instrument [Line Items]
Notes Payable	$ 37,673	$ 25,538

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1)	Jun. 30, 2015USD ($)
Aggregate maturities of long-term debt:
Six months ended December 31, 2015	$ 404,326
Year ended December 31, 2016	7,779,410
Year ended December 31, 2017	654,891
Year ended December 31, 2018 and thereafter	91,878
Total	$ 8,930,505

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)

Jun. 11, 2013

Aug. 12, 2011

Jan. 30, 2015

Feb. 25, 2013

Sep. 27, 2012

Aug. 22, 2012

Jun. 27, 2012

May. 21, 2012

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2015

Dec. 31, 2014

Apr. 09, 2013

Mar. 08, 2013

Sep. 24, 2012

May. 29, 2012

Oct. 25, 2011

Debt Instrument [Line Items]

Notes Payable

$ 8,930,505

$ 8,917,351

Debt Instrument, Periodic Payment, Principal

$ 580,000

X Ray Equipment [Member]

Debt Instrument [Line Items]

Capital Lease Obligations

$ 212,389

Debt Instrument, Interest Rate, Stated Percentage

7.9375%

Capital Lease Obligations Due In First 3 Months

$ 0

$ 1,384

Capital Lease Obligations Due For Remaining Months

$ 4,300

4,575

Debt Instrument, Term

60 months

MRI Equipment [Member]

Debt Instrument [Line Items]

Capital Lease Obligations

$ 1,771,390

Debt Instrument, Interest Rate, Stated Percentage

7.9375%

Capital Lease Obligations Due In First 3 Months

$ 0

11,779

Capital Lease Obligations Due For Remaining Months

$ 38,152

$ 38,152

Debt Instrument, Term

60 months

C-Arm Equipment [Member]

Debt Instrument [Line Items]

Capital Lease Obligations

$ 124,797

Debt Instrument, Interest Rate, Stated Percentage

7.39%

Capital Lease Obligations Due In First 3 Months

$ 0

Capital Lease Obligations Due For Remaining Months

$ 2,388

Debt Instrument, Term

63 months

Equipment Capital Lease [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment

$ 956

Debt Instrument, Maturity Date

Jun. 1, 2017

Debt Instrument, Interest Rate, Effective Percentage

14.002%

Capital Lease Equipment, Lease Term

48 months

Mortgage payable [Member]

Debt Instrument [Line Items]

Notes Payable

7,205,024

7,256,416

Debt Instrument, Interest Rate During Period

6.10%

Debt Instrument, Periodic Payment

$ 45,753

Debt Instrument, Maturity Date

Sep. 16, 2016

Interest and Debt Expense

$ 286,723

Debt Instrument, Term

30 years

Debt Instrument, Face Amount

$ 7,550,000

Note Payable GE Capital [Member] | Equipment Finance Lease [Member]

Debt Instrument [Line Items]

Capital Lease Obligations

2,288,679

Note Payable GE Capital Construction MRI [Member]

Debt Instrument [Line Items]

Notes Payable

30,869

121,204

Construction Loan

$ 450,000

Note Payable GE Capital Construction 2 [Member]

Debt Instrument [Line Items]

Notes Payable

15,249

44,911

Construction Loan

$ 150,000

Note Payable Auto [Member]

Debt Instrument [Line Items]

Notes Payable

$ 13,331

$ 16,383

Debt Instrument, Interest Rate During Period

6.99%

Debt Instrument, Maturity Date

Jun. 30, 2017

Debt Instrument, Periodic Payment, Principal

$ 593

Debt Instrument, Face Amount

29,850

GE Healthcare Financial Services [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate During Period

7.38%

Debt Instrument, Term

35 months

Debt Instrument, Face Amount

$ 2,400,000

Florida Business Bank [Member]

Debt Instrument [Line Items]

Debt Instrument, Periodic Payment

$ 14,753

Debt Instrument, Periodic Payment, Principal

$ 11,434

Debt Instrument, Interest Rate, Stated Percentage

5.50%

3.89%

Proceeds from Notes Payable

$ 900,931

Bank Owned Life Insurance

$ 634,000

Lease To Acquire Equipment

$ 1,036

CAPITAL STOCK (Details Textual)

CAPITAL STOCK (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	811,200
Deferred Compensation Share-based Arrangements, Liability, Current	$ 147,500		$ 537,750
Stock Issued During Period, Value, Issued for Services	530,000
Accrued Liabilities	31,200
Convertible Notes Payable	780,000
Officers, Employees And Service Providers [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued for Services	$ 530,000	$ 221,000
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	200,000
Stock Issued During Period, Shares, Issued for Services	506,000
Stock Issued During Period, Value, Issued for Services	$ 506
Common Stock [Member] | Employee Stock Option [Member]
Class of Stock [Line Items]
Deferred Compensation Arrangement with Individual, Shares Issued	147,500
Deferred Compensation Share-based Arrangements, Liability, Current	$ 147,500		$ 537,750
Deferred Compensation Arrangement with Individual, Exercise Price	$ 1		$ 1.32

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - Warrant [Member] - $ / shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding	4,195,000	4,195,000	4,195,000
Warrants Outstanding, Weighted Price (in dollars per share)	$ 2.36	$ 2.36	$ 2.36
Warrants Exercisable	4,195,000
Warrants Exercisable, Weighted Price (in dollars per share)	$ 2.36
Exercise Price Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Prices (in dollars per share)	$ 1.35
Warrants Outstanding	2,320,000
Warrants Outstanding, Expiration Date	Nov. 8, 2018
Warrants Outstanding, Weighted Price (in dollars per share)	$ 1.35
Warrants Exercisable	2,320,000
Warrants Exercisable, Weighted Price (in dollars per share)	$ 1.35
Exercise Price Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Prices (in dollars per share)	$ 3.60
Warrants Outstanding	1,875,000
Warrants Outstanding, Expiration Date	Dec. 31, 2016
Warrants Outstanding, Weighted Price (in dollars per share)	$ 3.60
Warrants Exercisable	1,875,000
Warrants Exercisable, Weighted Price (in dollars per share)	$ 3.60

STOCK OPTIONS AND WARRANTS (D39

STOCK OPTIONS AND WARRANTS (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Granted (in dollars per share)	$ 1.35
Weighted Average Price Per Share, Expired (in dollars per share)	0
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Granted (in dollars per share)	0	$ 0
Weighted Average Price Per Share, Exercised (in dollars per share)	0	0
Weighted Average Price Per Share, Expired (in dollars per share)	$ 0	$ 0
Number of Shares, Outstanding, Beginning balance	4,195,000	4,195,000
Number of Shares, Granted	0	0
Number of Shares, Exercised	0	0
Number of Shares, Expired	0	0
Number of Shares, Outstanding, Ending balance	4,195,000	4,195,000
Weighted Average Price Per Share, Outstanding, Beginning balance (in dollars per share)	$ 2.36	$ 2.36
Weighted Average Price Per Share, Ending balance (in dollars per share)	$ 2.36	$ 2.36

STOCK OPTIONS AND WARRANTS (D40

STOCK OPTIONS AND WARRANTS (Details 2) - USD ($)	6 Months Ended
	Jun. 30, 2015
Number of Shares, Outstanding, Beginning balance	0
Number of Shares, Granted	3,000,000
Number of Shares, Canceled/expired	0
Number of Shares, Outstanding, Ending balance	3,000,000
Number of Shares, Exercisable	0
Weighted Average Price Per Share, Outstanding, Beginning balance (in dollars per share)	$ 0
Weighted Average Exercise Granted (in dollars per share)	1.35
Weighted Average Exercise Canceled/expired (in dollars per share)	0
Weighted Average Price Per Share, Ending balance (in dollars per share)	1.35
Weighted Average Price Per Share, Execisable	$ 0
Weighted Average Remaining Contractual Term Granted	8 years 8 months 1 day
Weighted Average Remaining Contractual Term Outstanding	8 years 6 months
Weighted Average Remaining Contractual Term Exercisable
Aggregate Intrinsic Value Outstanding-Beginning	$ 0
Aggregate Intrinsic Value Outstanding-Granted	0
Aggregate Intrinsic Value Canceled/expired	0
Aggregate Intrinsic Value Outstanding-Ending	0
Aggregate Intrinsic Value Exercisable	$ 0

STOCK OPTIONS AND WARRANTS (D41

STOCK OPTIONS AND WARRANTS (Details 3) - $ / shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Options Outstanding Exercise Price	$ 1.35	$ 0
Options Outstanding Number of Options	3,000,000	0
Options Outstanding Weighted Average Remaining Life in Years	8 years 6 months
Options Exercisable	0

STOCK OPTIONS AND WARRANTS (D42

STOCK OPTIONS AND WARRANTS (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,000,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 1.35	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 3,226,427
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	134.09%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.12%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	8 years 8 months 1 day
Warrants Not Settleable in Cash [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,875,000
Warrants Settleable in Cash [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,320,000

VARIABLE INTEREST ENTITY (Detai

VARIABLE INTEREST ENTITY (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash	$ 1,054,565	$ 279,087	$ 70,812	$ 739,158
Accounts receivable	4,489,477	1,804,636
Total current assets	6,792,775	2,623,648
Property and equipment, net	8,103,672	8,294,298
Total assets	18,587,547	11,470,692
Current liabilities:
Accounts payable and accrued liabilities	2,502,168	1,457,275
Total current liabilities	7,776,206	6,376,414
Long term debt	8,930,505
Total liabilities	17,560,829	14,633,875
Deficit	1,026,718	(3,163,183)
Total liabilities and stockholders' equity	18,733,531	$ 11,470,692
Variable Interest Entity, Primary Beneficiary [Member]
Current assets:
Cash	999,128
Accounts receivable	2,038,218
Due from First Choice Healthcare Solutions	25,368
Other current assets	632,853
Total current assets	3,695,567
Property and equipment, net	31,463
Other Assets	23,026
Total assets	3,750,056
Current liabilities:
Accounts payable and accrued liabilities	970,626
Other current liabilities	1,086,469
Total current liabilities	2,057,095
Long term debt	1,831,647
Total liabilities	3,888,742
Deficit	(138,686)
Total liabilities and stockholders' equity	$ 3,750,056

VARIABLE INTEREST ENTITY (Det44

VARIABLE INTEREST ENTITY (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 1.35		$ 1.35		$ 0
Health Care Organization, Revenue Net of Patient Service Revenue Provisions	$ 4,324,314	$ 2,107,164	$ 6,829,482	$ 4,341,917
Labor and Related Expense	2,125,481	1,090,806	3,071,601	2,156,327
Depreciation, Depletion and Amortization, Nonproduction, Total	144,417	126,772	284,926	261,491
Interest Income (Expense), Nonoperating, Net	$ (358,994)	$ (217,177)	$ (722,138)	$ (436,430)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,000,000		3,000,000		0
Variable Interest Entity, Primary Beneficiary [Member]
Health Care Organization, Revenue Net of Patient Service Revenue Provisions			$ 2,206,102
Labor and Related Expense			1,250,618
Selling, General and Administrative Expense, Total			969,706
Depreciation, Depletion and Amortization, Nonproduction, Total			3,223
Interest Income (Expense), Nonoperating, Net			$ 7,923

SEGMENT REPORTING (Details)

SEGMENT REPORTING (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Revenue:
Net patient service revenue	$ 3,804,039	$ 1,848,441	$ 6,044,103	$ 3,821,271
Rental revenue	520,276	258,723	785,379	520,646
Total revenue	4,324,314	2,107,164	6,829,482	4,341,917
Operating expenses:
Salaries & benefits	2,125,481	1,090,806	3,071,601	2,156,327
Other operating expenses	563,422	427,056	1,014,907	856,347
General and administrative	1,649,870	669,208	2,203,154	1,075,120
Depreciation and amortization	144,417	126,772	284,926	261,491
Total operating expenses	4,483,190	2,313,842	6,574,588	4,349,285
Net income (loss) from operations	(158,875)	(206,678)	254,894	(7,368)
Interest expense	(358,994)	(217,177)	(722,138)	(436,430)
Amortization of financing costs	(19,229)	(25,466)	(39,915)	(41,372)
Other income (expense)	40,369	750	41,119	1,500
Net loss before provision for income taxes	(496,729)	(448,571)	(466,040)	(483,670)
Income taxes	0	0	0	0
Net loss	(496,729)	(448,571)	(466,040)	(483,670)
Assets acquired
Assets, Total	18,587,547		18,587,547		$ 11,470,692
Assets acquired	31,780	76,984	40,065	87,982
Marina Towers [Member]
Revenue:
Net patient service revenue	0	0	0	0
Rental revenue	375,512	367,460	750,833	736,971
Total revenue	375,512	367,460	750,833	736,971
Operating expenses:
Salaries & benefits	3,000	3,000	6,000	6,000
Other operating expenses	109,943	109,989	213,274	213,601
General and administrative	24,148	21,903	46,790	43,722
Depreciation and amortization	69,674	69,219	138,893	138,228
Total operating expenses	206,765	204,111	404,957	401,551
Net income (loss) from operations	168,747	163,349	345,876	335,420
Interest expense	(109,300)	(114,067)	(219,796)	(226,091)
Amortization of financing costs	(14,337)	(14,337)	(28,674)	(28,674)
Other income (expense)	21,219	750	21,969	1,500
Net loss before provision for income taxes	66,329	35,695	119,375	82,155
Income taxes	0	0	0	0
Net loss	66,329	35,695	119,375	82,155
Assets acquired
Assets, Total	6,508,932		6,508,932		6,726,759
Assets acquired	29,781	6,319	36,409	16,758
FCID Medical [Member]
Revenue:
Net patient service revenue	1,873,219	1,848,441	4,113,283	3,821,271
Rental revenue	0	0	0	0
Total revenue	1,873,219	1,848,441	4,113,283	3,821,271
Operating expenses:
Salaries & benefits	781,064	996,555	1,618,051	1,976,438
Other operating expenses	564,847	425,804	1,023,219	859,071
General and administrative	319,237	328,909	610,396	565,161
Depreciation and amortization	66,745	57,553	133,260	123,263
Total operating expenses	1,731,893	1,808,821	3,384,926	3,523,933
Net income (loss) from operations	141,326	39,620	728,357	297,338
Interest expense	(68,798)	(55,951)	(120,582)	(115,288)
Amortization of financing costs	(4,233)	(11,129)	(10,582)	(12,698)
Other income (expense)	0	0	0	0
Net loss before provision for income taxes	68,295	(27,460)	597,193	169,352
Income taxes	0	0	0	0
Net loss	68,295	(27,460)	597,193	169,352
Assets acquired
Assets, Total	4,873,844		4,873,844		4,407,749
Assets acquired	1,999	70,665	3,656	71,224
Corporate [Member]
Revenue:
Net patient service revenue	0	0	0	0
Rental revenue	0	0	0	0
Total revenue	0	0	0	0
Operating expenses:
Salaries & benefits	90,799	91,251	196,932	173,889
Other operating expenses	0	0	0	0
General and administrative	389,029	318,396	628,512	466,237
Depreciation and amortization	4,775	0	9,550	0
Total operating expenses	484,603	409,647	834,994	640,126
Net income (loss) from operations	(484,603)	(409,647)	(834,994)	(640,126)
Interest expense	(173,632)	(47,159)	(374,496)	(95,051)
Amortization of financing costs	0	0	0	0
Other income (expense)	0	0	0	0
Net loss before provision for income taxes	(658,235)	(456,806)	(1,209,490)	(735,177)
Income taxes	0	0	0	0
Net loss	(658,235)	(456,806)	(1,209,490)	(735,177)
Assets acquired
Assets, Total	3,480,083		3,480,083		336,184
Assets acquired	0	0	0	0
Intercompany Eliminations [Member]
Revenue:
Net patient service revenue	0	0	0	0
Rental revenue	(111,368)	(108,737)	(221,586)	(216,325)
Total revenue	(111,368)	(108,737)	(221,586)	(216,325)
Operating expenses:
Salaries & benefits	0	0	0	0
Other operating expenses	(111,368)	(108,737)	(221,586)	(216,325)
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	(111,368)	(108,737)	(221,586)	(216,325)
Net income (loss) from operations	0	0	0	0
Interest expense	0	0	0	0
Amortization of financing costs	0	0	0	0
Other income (expense)	0	0	0	0
Net loss before provision for income taxes	0	0	0	0
Income taxes	0	0	0	0
Net loss	0	0	0	0
Assets acquired
Assets, Total	0		0		0
Assets acquired	0	0	0	0
Brevard Orthopaedic [Member]
Revenue:
Net patient service revenue	1,930,820	0	1,930,820	0
Rental revenue	256,132	0	256,132	0
Total revenue	2,186,952	0	2,186,952	0
Operating expenses:
Salaries & benefits	1,250,618	0	1,250,618	0
Other operating expenses	0	0	0	0
General and administrative	917,456	0	917,456	0
Depreciation and amortization	3,223	0	3,223	0
Total operating expenses	2,171,297	0	2,171,297	0
Net income (loss) from operations	15,655	0	15,655	0
Interest expense	(7,264)	0	(7,264)	0
Amortization of financing costs	(659)	0	(659)	0
Other income (expense)	19,150	0	19,150	0
Net loss before provision for income taxes	26,882	0	26,882	0
Income taxes	0	0		0
Net loss	26,882	0	26,882	0
Assets acquired
Assets, Total	3,724,688		3,724,688		$ 0
Assets acquired	$ 0	$ 0	$ 0	$ 0

COMMITMENTS AND CONTINGENCIES46

COMMITMENTS AND CONTINGENCIES (Details)	Jun. 30, 2015USD ($)
Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]
Six months ended December 31 2015:	$ 1,732,268
Year ended December 31, 2016	3,494,547
Year ended December 31, 2017	3,444,197
Year ended December 31, 2018	3,444,209
Year ended December 31, 2019	3,444,221
Operating Leases, Future Minimum Payments Due, Total	$ 15,559,442

COMMITMENTS AND CONTINGENCIES47

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Jul. 25, 2014	Jun. 30, 2015
Commitments and Contingencies [Line Items]
Lease Rent Expense Per Month		$ 4,200
Operating Leases, Rent Expense, Net, Total		260,234
Maximum [Member]
Commitments and Contingencies [Line Items]
Lease Rent Expense Per Month		200,000
MedTRX [Member]
Commitments and Contingencies [Line Items]
Due to Related Parties	$ 93,280.84
Loss Contingency, Damages Sought, Value	$ 3,000,000
Loss Contingency Accrual, Beginning Balance		$ 118,000

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - Aug. 03, 2015 - Subsequent Event [Member] - Hillair Capital Investments, LP [Member] - Short-Term Debt, Type [Domain] - Debt Instrument, Name [Domain] - USD ($)	Total
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Convertible, Conversion Price	$ 1
Convertible Debt, Current	$ 1,161,641
Gains (Losses) on Extinguishment of Debt, Total	$ 1,161,641
Debt Instrument, Maturity Date	Nov. 1, 2015